All News
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju
Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
Dr. John Cush RheumNow ( View Tweet)
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis
Dr. Mike Putman discusses abstract 0670, presented at #ACR24.
https://t.co/aLzsSSOmML https://t.co/XrEtNZAgHI
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. Content is chosen by RheumNow & its facult.y
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR24 - Day 3 Report
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24
https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii
Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate.
https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
Are Emulation Trials a Fantasy?
Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
https://t.co/x6NogGQksW https://t.co/f8o8N55tlJ
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1
Bella Mehta bella_mehta ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
#Publication #bias to Nth degree.
>1/3 of registered #postmeno #osteoporosis trials are NOT #published
👇search of trials
673 published
Vs
489 not published 890000 pts
MOSTLY when performed in the USA
No accountability for NOT publishing
#ACRbest #ACR24 @RheumNow #2122 https://t.co/UyMMbHhvvV
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis.All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
